The Latest Breaking News from Inhibrx Biosciences

Adding an Experimental OX40 Drug to Keytruda Nearly Doubled Tumor Responses in Advanced Head and Neck Cancer

An experimental OX40 drug plus Keytruda nearly doubled tumor responses in head and neck cancer. The company's data are early and not peer-reviewed.

Medical Daily · Sep 10

Inhibrx Biosciences’ INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study

Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck’s KEYTRUDA in first-line PD-L1-positive head and neck squamous cell carcinoma, with Chief Executive Officer Mark Lappe saying the results showed a higher confirmed response rate and dee

MarketBeat · May 11

Why Are Inhibrx Biosciences Shares Soaring 76% After Hours?

Inhibrx Biosciences Inc. (NASDAQ:INBX) shares rose 75.95% in after-hours trading on Thursday, closing at $49.90.

Benzinga · Oct 24, 2025